Effectiveness of Internet-Delivered Cognitive Behavioural Therapy (ICBT) in Improving Weight-Loss and Psychosocial Well-Being Among Adults With High BMI: A Systematic Review.

J Clin NursJun 7, 2026 (epub)
Clinical ResearchPsychiatryEndocrinologyOpen access

Sivaraman Suvetha, Ganesh Mishra, Piyanee Klanin-Yobas et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effectiveness of Internet-delivered Cognitive Behavioural Therapy (ICBT) in improving weight loss and psychosocial well-being among adults with a BMI ≥ 25 kg/m². Analyzing nine randomized controlled trials with 2278 participants, the review found significant improvements in BMI, weight, and depressive symptoms, while self-esteem effects were small and non-significant.

Key findings

  • ICBT led to significant reductions in BMI and weight compared to passive controls.
  • Improvements in depressive symptoms were noted, but self-esteem effects were small and non-significant.
  • Male-tailored interventions showed greater improvements in outcomes.
  • Shorter ICBT programs resulted in larger short-term weight loss.

Why it matters

The findings suggest that ICBT can be an effective intervention for weight management and mental health in adults with high BMI, addressing both physical and psychosocial aspects of obesity.

Source

PubMed · PMID 42252570Free full text on PubMed Central

Published in J Clin Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.